Clinicopathologic Features and Immunohistochemical Markers
|
β1 Integrin-
|
β1 Integrin+
|
P-value
|
---|
| |
n (151)
|
(%)
|
n (74)
|
(%)
| |
---|
Age (years)
|
<50
|
65
|
43.0
|
27
|
36.5
|
0.213a
|
>50
|
86
|
67.0
|
47
|
63.5
| |
Menstrual Status
|
Pre-menopausal
|
54
|
35.8
|
24
|
32.4
|
0.367a
|
Post-menopausal
|
97
|
64.2
|
50
|
67.6
| |
Size (mm)
|
<20
|
49
|
32.5
|
19
|
25.7
|
0.442b
|
20-50
|
55
|
36.4
|
33
|
44.6
| |
>50
|
47
|
31.1
|
22
|
29.7
| |
Tumoral Grade
|
I
|
57
|
37.7
|
25
|
33.8
|
0.845b
|
II
|
71
|
47.0
|
37
|
50.0
| |
III
|
23
|
15.2
|
12
|
16.2
| |
Lymph node Status
|
Negative
|
75
|
49.7
|
33
|
44.6
|
0.283a
|
Positive
|
76
|
50.3
|
41
|
55.4
| |
Clinical Stage
|
I
|
22
|
14.6
|
10
|
13.5
|
0.677b
|
II
|
72
|
47.7
|
30
|
40.5
| |
III
|
49
|
32.5
|
30
|
40.5
| |
IV
|
8
|
5.3
|
4
|
5.4
| |
Death
|
No
|
116
|
76.8
|
40
|
54.1
|
0.001
a
|
Yes
|
35
|
23.2
|
34
|
45.9
| |
Metastasis
|
No
|
115
|
76.2
|
48
|
64.9
|
0.05
a
|
Yes
|
36
|
23.8
|
26
|
35.1
| |
ER
|
Negative
|
48
|
31.8
|
21
|
28.4
|
0.359a
|
Positive
|
103
|
68.2
|
53
|
71.6
| |
PR
|
Negative
|
64
|
42.4
|
33
|
44.6
|
0.431a
|
Positive
|
87
|
57.6
|
41
|
55.4
| |
p53
|
Negative
|
114
|
75.5
|
51
|
68.9
|
0.187a
|
Positive
|
37
|
24.5
|
23
|
31.1
| |
Ki-67
|
Negative
|
107
|
70.9
|
54
|
73.0
|
0.435a
|
Positive
|
44
|
29.1
|
20
|
27.0
| |
HER2
|
Negative
|
126
|
83.4
|
52
|
70.3
|
0.019
a
|
Positive
|
25
|
16.6
|
22
|
29.7
| |
VEGF
|
Negative
|
114
|
75.5
|
66
|
89.2
|
0.011
a
|
|
Positive
|
37
|
24.5
|
8
|
10.8
| |
- aFisher’s exact test; bChi-square test.